18F-Fluciclovine PET/CT in the Assessment of Pancreatic Transplants

• Status: Enrolling by invitation
• Trial end date: 2022-08-31
• Target enrollment: 0
• Participant gender: All

Summary

Hypothesis 1: 18F-Fluciclovine PET/CT can correctly and easily identify the pancreatic allograft and determine its viability

Aim 1: Assess whether 18F-Fluciclovine can identify the pancreatic allograft accurately and assess its viability and visibility

Hypothesis 2: 18F-Fluciclovine PET/CT uptake in the pancreas (SUV) is related to total pancreatic function and therefore can indicate whether the pancreatic allograft is at risk of rejection

Aim 2: Assess whether 18F-Fluciclovine uptake in the pancreas can be a surrogate for pancreatic function

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Utah

Criteria

Inclusion Criteria:

• 18 or over in age

• Have any type of pancreatic transplant

• Able to consent for 18F-Fluciclovine PET/CT scan

• For archived 18F-Fluciclovine PET/CT scan reviews, only scans of non-diabetic patients will be included.

Exclusion Criteria:

• Patient with known prostate cancer